Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SET Antibodies:
anti-Mouse (Murine) SET Antibodies:
anti-Rat (Rattus) SET Antibodies:
Go to our pre-filtered search.
Human Polyclonal SET Primary Antibody for WB - ABIN4620361
von Lindern, van Baal, Wiegant, Raap, Hagemeijer, Grosveld: Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. in Molecular and cellular biology 1992
Show all 12 Pubmed References
The acidic domain of SET bound directly to the CTD of p53 (show TP53 Antibodies), and expression of CREB-binding protein (CBP (show CREBBP Antibodies)), which acetylates the p53 (show TP53 Antibodies) CTD, prevented SET binding to wild-type but not acetylation-deficient p53 (show TP53 Antibodies), further indicating that SET binds specifically to the unacetylated p53 (show TP53 Antibodies) CTD.
Overexpression of SET-Nup214 in HeLa cells leads to the formation of similar nuclear bodies that recruit CRM1, export cargo proteins, and certain nucleoporins and concomitantly affect nuclear protein and poly(A)(+) RNA export.
Molecular chaperone (show HSP90AA1 Antibodies) SET-assisted eviction of linker histones and Shugoshins is a fundamental step in mammalian mitotic progression.
Our findings suggested the oncogenic role of SET and the adverse prognostic value of SET overexpression in hepatocellular carcinoma (HCC (show FAM126A Antibodies)). This alteration defines a subgroup of HCC (show FAM126A Antibodies) patients who could benefit from SET antagonists, such as EMQA.
This review summarizes and discusses the general mechanisms of H3K4 methylation, and how the six main enzymes from the SET/MLL (show MLL Antibodies) family (responsible for H3K4me1/me2 (show CELSR1 Antibodies)/me3 (show ME3 Antibodies)) function in hematopoiesis and in hematologic malignancies. [review]
identification of the oncoprotein SET as a major cellular factor whose binding with p53 (show TP53 Antibodies) is dependent on C-terminal domain acetylation status
Data indicate that SET protein as a direct target of microRNA miR (show MLXIP Antibodies)-125b, and the downregulation of SET, observed during tumor migration, was affected by the overexpression of miR125b.
significance of SET/I2PP2A-mediated PP2A (show PPP2R4 Antibodies) and non-PP2A (show PPP2R4 Antibodies) pathways in polycystic ovary syndrome
Data show that downregulating proto-oncogene (show RAB1A Antibodies) protein Akt (p-Akt (show AKT1 Antibodies)) by inhibiting PP2A (show PPP2R4 Antibodies) inhibitor SET-mediated protein phosphatase 2A (PP2A (show PPP2R4 Antibodies)) inactivation determined the pro-apoptotic effects of EMQA and paclitaxel combination treatment.
Data suggest a critical role for the I2PP2A protein (SET)-protein phosphatase-2A (PP2A (show PPP2R4 Antibodies)) signaling axis in Pten (show PTEN Antibodies) protein (Pten (show PTEN Antibodies)) deficient castration resistant prostate cancer (CRPC) progression.
Data suggest a critical role for the I2PP2A protein (SET)-protein phosphatase-2A (PP2A (show PPP2R2B Antibodies)) signaling axis in Pten (show PTEN Antibodies) protein (Pten (show PTEN Antibodies)) deficient castration resistant prostate cancer (CRPC) progression.
The presence of full-length SET in the neuronal cytoplasm is sufficient to impair PP2A (show PPP2R2B Antibodies) methylation and activity, leading to tau hyperphosphorylation.
SET/PP2A (show PPP2R2B Antibodies) system regulates testosterone production in ovarian follicles in vitro.
SET played a positive role in regulating ovarian androgen biosynthesis by enhancing the transcription of steroidogenic enzymes CYP17A1 (show CYP17A1 Antibodies) and HSD3B2 (show HSD3B2 Antibodies), which maybe contribute to the hyperandrogenism in polycystic ovary syndrome
study found SET, a putative oncogene (show RAB1A Antibodies) was significantly downregulated in a bisphenol A dose-dependent manner; from gene network analysis, SET is predicted to communicate with other genes including CYP17 (show CYP17A1 Antibodies), which is involved in biosynthesis and metabolism of sex-hormones
Our results suggest that the increased I(2)(PP2A (show PPP2R2B Antibodies)) may trigger apoptosis by p53 (show TP53 Antibodies) upregulation, but due to simultaneous activation of Akt (show AKT1 Antibodies), the neurons are aborted from the apoptotic pathway.
SET is an important regulator of chromosome condensation (show RCC1 Antibodies)/decondensation and that disruption of the MCPH1 (show MCPH1 Antibodies)-SET interaction might be important for the pathogenesis of primary microcephaly
By a novel molecular mechanism, apolipoprotein (apo)E (show APOE Antibodies)/peptide enhances protein phosphatase 2A (PP2A (show PPP2R2B Antibodies)) activity within a cell by binding/forming a complex with SET, reducing the amount of SET available to inhibit PP2A (show PPP2R2B Antibodies), signaling, and inflammatory response.
These studies indicated that the TAF (show TAF8 Antibodies)-Ialpha promoter is under the control of Sp1 (show SP1 Antibodies).(TAF (show TAF8 Antibodies)-Ialpha )
The protein encoded by this gene inhibits acetylation of nucleosomes, especially histone H4, by histone acetylases (HAT). This inhibition is most likely accomplished by masking histone lysines from being acetylated, and the consequence is to silence HAT-dependent transcription. The encoded protein is part of a complex localized to the endoplasmic reticulum but is found in the nucleus and inhibits apoptosis following attack by cytotoxic T lymphocytes. This protein can also enhance DNA replication of the adenovirus genome. Several transcript variants encoding different isoforms have been found for this gene.
protein phosphatase 2A inhibitor 2-like
, HLA-DR-associated protein II
, SET translocation (myeloid leukemia-associated)
, Template-Activating Factor-I, chromatin remodelling factor
, inhibitor of granzyme A-activated DNase
, inhibitor-2 of protein phosphatase-2A
, phosphatase 2A inhibitor I2PP2A
, protein SET
, protein phosphatase type 2A inhibitor
, SET translocation
, template-activating factor I
, liver regeneration-related protein LRRGR00002